The Lupus Research Alliance has announced the recipients of its 2025 Empowering Lupus Research Awards, which will support innovative studies on gut bacteria, immune cells, chronic pain, and inflammatory pathways. The awards aim to fuel discoveries that improve outcomes for people living with lupus.
Dr. Deepak Rao's groundbreaking research reveals an unknown imbalance in immune cells contributing to lupus, identifying a potential target for restoring immune system regulation. The discovery provides a promising new direction for therapeutic development and brings the Lupus Research Alliance one step closer to targeted therapies.
The Lupus Research Alliance has launched the Lupus Nexus Foundational Analyses, integrating molecular datasets with clinical data to accelerate personalized lupus treatments. This initiative provides a comprehensive and accessible dataset, generating new hypotheses and driving meaningful breakthroughs for people living with lupus.
The Lupus Research Alliance awards $150,000 to 11 talented researchers investigating novel therapeutic strategies, chronic inflammation, biomarkers for diagnosis and monitoring. The studies aim to accelerate lupus research and potentially transform treatment approaches.
The Lupus Research Alliance has awarded grants to 11 researchers working on engineered cell therapies for lupus. These studies focus on developing safer and more effective treatments using techniques such as CAR T cells, which involve reprogramming a patient's own immune cells to attack disease-causing cells.
The IDEAL Initiative will fund pilot clinical studies assessing the impact of diet intervention on lupus lived experience. The initiative aims to identify a practical dietary approach that benefits people with lupus.
The Lupus Research Alliance has awarded the inaugural Translational Bridge Award to five researchers tackling pressing lupus issues, including pain management, nephritis diagnostics, glucocorticoid alternatives, novel therapies, and brain fog diagnosis.
The Lupus Research Alliance will present 33 studies at ACR Convergence 2024, covering foundational research, clinical trials, and CAR T cell therapy approaches for treating lupus. These studies represent significant advancements in understanding and addressing the complexities of this autoimmune disease.
The Lupus Research Alliance has awarded four talented scientists from underrepresented minority groups to promote diversity in lupus research. Alí Duarte-García, Maria Gutierrez-Arcelus, Ekemini Ogbu, and Jessica Williams will receive Career Development Awards to investigate glucocorticoid treatment, lupus heterogeneity, cerebrovascula...
The Lupus Research Alliance has announced 11 recipients of the 2021 Lupus Innovation Award, supporting innovative approaches to understanding lupus and developing personalized therapies. The award will fund studies aiming to illuminate genetic causes of lupus and develop targeted treatments.
The Lupus Research Alliance is funding two projects that examine why lupus varies for each person. Researchers will investigate the differences in genetic and environmental factors contributing to lupus variability.
A survey conducted by the Lupus Research Alliance found that two-thirds of people with lupus would take a COVID-19 vaccine if it were free and deemed safe by scientists. However, 24% said they would not get vaccinated, citing concerns over side effects and safety, while 22% remained uncertain.
Researchers are using cutting-edge technology to analyze immune cell interactions in lupus patients, identifying potential targets for new therapies. The Lupus Mechanisms and Targets Award will support innovative studies aimed at improving diagnostics and treatments for the disease.
A new study by Marko Radic and colleagues shows that CAR T cells can significantly reduce disease symptoms and progression in mice with lupus, improving lifespan and reducing inflammation. The findings offer a renewed optimism for eliminating B cells as a therapeutic option for lupus.
The Lupus Research Alliance is funding innovative approaches to treating lupus, including 'borrowed' drugs from other diseases and research into harmful immune cells. Seven scientists will receive awards to test promising strategies for treating lupus, with potential breakthroughs in clinical trials.
Nir Hacohen and Vijay Kuchroo receive Distinguished Innovator Award for innovative approaches to treating lupus kidney disease and harnessing regulatory T and B cells. Their research aims to stimulate strategies for prevention, treatment, and cure of the chronic autoimmune disease.
The Lupus Insight Prize recognizes Dr. Marshak-Rothstein's work on Toll-like receptors and their role in regulating lupus pathogenesis, aiming to develop more effective treatments.
The Lupus Research Institute has awarded 12 novel research grants to investigate the link between bacteria and lupus, as well as innovative approaches to treating the disease. The grants aim to develop new treatments and potentially prevent lupus through cutting-edge research.
The S.L.E. Lupus Foundation has awarded grants to three New York City-based researchers to explore potential treatments and causes of lupus. The foundation's investment has surpassed $17 million, making it a leader in lupus research and care.
A new clinical test that predicts lupus flares has been licensed for development, providing patients and physicians with a crucial tool for managing the disease. The test, which measures chemokine levels in blood, may help reduce corticosteroid exposure and prevent flare intensity.
Scientists have identified a new type of cell in mice that dampens the immune system and protects its own cells from immune system attack. This breakthrough discovery holds promise for new therapies to control hyperactive immune systems in autoimmune diseases like lupus.
A recent study funded by the Lupus Research Institute has discovered a link between an X-linked TLR7 gene variant and an increased risk of developing lupus in men. The research, published in the Proceedings of the National Academy of Sciences, provides strong evidence that alterations in the TLR7 gene can promote lupus in humans.
The Lupus Research Institute has awarded $3.6 million in grants to support innovative research on systemic lupus erythematosus (SLE). The grants will fund studies on novel genes associated with African-American lupus, non-invasive assessment of lupus nephritis, and the role of nervous system networks in inflammation.
Researchers funded by Lupus Research Institute discover a molecular switch controlling inflammatory response, potentially treating chronic autoimmune disorders like lupus. The finding may lead to new methods to shut down uncontrolled inflammation and restore immune system regulation.
The Lupus Research Institute's groundbreaking strategy has yielded significant progress in novel lupus research, with 61% of investigators turning hypotheses into confirmed discoveries. The institute's support has enabled the development of breakthroughs in genetics, molecular science, and other fields.
The Lupus Research Institute has awarded $4.5 million in grants to 15 scientists to pursue novel lupus research, with a focus on genes, bacteria, and neuropsychiatric lupus. The funding will support both basic and applied studies that aim to advance new treatments for the disease.
Researchers have found that women with lupus are at high risk of heart disease due to the presence of pro-inflammatory HDL in their blood. The discovery may lead to an effective test to identify patients at increased risk and prevent cardiovascular morbidity and mortality.
The Lupus Research Institute is awarding $4.5 million to support groundbreaking studies on autoimmune disease, which affects 1.5 million Americans. The grants will be used to investigate the cause, prevention and treatment of lupus, with a focus on novel approaches and collaborations.